SCHEMBL20239308

SCHEMBL20239308

COc1nc(CN)cc(Oc2ccc(CS(=O)(=O)N(C)C(=O)O)cc2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.34
PLA2G10 O15496 2/20 0.34
ALDH1A1 P00352 3/20 0.33
GAA P10253 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
KMT2A Q03164 3/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.33
TXNRD1 Q16881 1/20 0.33
MEN1 O00255 2/20 0.33
PDE4B Q07343 1/20 0.32
PTPN1 P18031 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
ATM Q13315 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
DGAT2 Q96PD7 1/20 0.32
LMNA P02545 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738673 0.88 LOXL2 (0.34) SMN1; SMN2ALDH1A1LOXL2KMT2ATSHR
SCHEMBL20252442 0.88 SMN1; SMN2 (0.31) SMN1; SMN2ALDH1A1LOXL2KMT2ATSHR
SCHEMBL20239274 0.86 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1GAAKMT2APOLB
SCHEMBL20239292 0.86 PTPN1 (0.33) SMN1; SMN2PLA2G10ALDH1A1LOXL2KMT2A
SCHEMBL20239206 0.86 SMN1; SMN2 (0.37) SMN1; SMN2PLA2G10ALDH1A1LOXL2KMT2A
SCHEMBL20239225 0.85 LOXL2 (0.37) LOXL2KMT2AMEN1PDE4B
SCHEMBL20239142 0.84 ALDH1A1 (0.36) SMN1; SMN2PLA2G10ALDH1A1GAAKMT2A
SCHEMBL20239306 0.83 PDE4B (0.34) SMN1; SMN2LOXL2KMT2AMEN1PDE4B
SCHEMBL16738668 0.75 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1KMT2AMEN1PDE4B
SCHEMBL16738675 0.75 MMP13 (0.32) SMN1; SMN2ALDH1A1PDE4BDGAT2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT SMN1; SMN2 4828/4885PLA2G10 1502/4885ALDH1A1 1430/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT SMN1; SMN2 4835/4885PLA2G10 1539/4885ALDH1A1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.